摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[6-(5-methyl-3-pyridin-2-ylisoxazol-4-ylmethoxy)pyridin-3-yl]morpholin-4-ylmethanone | 1159602-81-9

中文名称
——
中文别名
——
英文名称
[6-(5-methyl-3-pyridin-2-ylisoxazol-4-ylmethoxy)pyridin-3-yl]morpholin-4-ylmethanone
英文别名
[6-(5-Methyl-3-pyridin-2-yl-isoxazol-4-ylmethoxy)-pyridin-3-yl]-morpholin-4-yl-methanone;[6-[(5-methyl-3-pyridin-2-yl-1,2-oxazol-4-yl)methoxy]pyridin-3-yl]-morpholin-4-ylmethanone
[6-(5-methyl-3-pyridin-2-ylisoxazol-4-ylmethoxy)pyridin-3-yl]morpholin-4-ylmethanone化学式
CAS
1159602-81-9
化学式
C20H20N4O4
mdl
——
分子量
380.403
InChiKey
VQORXIASXUHNLL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    28
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    90.6
  • 氢给体数:
    0
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    6-(5-methyl-3-pyridin-2-yl-isoxazol-4-ylmethoxy)-nicotinic acid methyl ester吗啉 以to the title compound (90 mg, 79%) which was obtained as a white solid的产率得到[6-(5-methyl-3-pyridin-2-ylisoxazol-4-ylmethoxy)pyridin-3-yl]morpholin-4-ylmethanone
    参考文献:
    名称:
    ISOXAZOLO-PYRIDINE DERIVATIVES
    摘要:
    本发明涉及式I的异唑嗪-吡啶衍生物,其中X,R1至R6如本文所述。这些化合物对GABA A α5受体结合位点具有活性,可用于治疗认知障碍,如阿尔茨海默病。
    公开号:
    US20130274468A1
点击查看最新优质反应信息

文献信息

  • ISOXAZOLE-PYRIDINE DERIVATIVES
    申请人:Buettelmann Bernd
    公开号:US20090143371A1
    公开(公告)日:2009-06-04
    The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R 1 to R 6 are as described herein. The compounds are active on the GABA A α5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.
    本发明涉及式I的异恶唑-吡啶衍生物 其中X,R1至R6如本文所述。这些化合物对GABA A α5受体结合位点具有活性,并可用于治疗认知障碍,如阿尔茨海默病。
  • Isoxazolo-pyridine derivatives
    申请人:Roche Palo Alto LLC
    公开号:US08877782B2
    公开(公告)日:2014-11-04
    The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R1 to R6 are as described herein. The compounds are active on the GABA A α5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.
    本发明涉及式I的异噁唑-吡啶衍生物,其中X,R1至R6如本文所述。该化合物对GABA A α5受体结合位点具有活性,可用于治疗认知障碍,如阿尔茨海默病。
  • Use of active pharmaceutical compounds for the treatment of central nervous system conditions
    申请人:F. Hoffmann-La Roche AG
    公开号:EP2457569A1
    公开(公告)日:2012-05-30
    The present invention relates to the pharmaceutical use of selective GABA A α5 negative allosteric modulators for the treatment, prevention and/or delay of progression of central nervous system (CNS) conditions caused by neurodevelopmental defects which result in excessive GABAergic inhibition in the cortex and hippocampus.
    本发明涉及选择性GABA A α5负异位调节剂的药物用途,用于治疗、预防和/或延缓由神经发育缺陷引起的中枢神经系统(CNS)疾病的进展,神经发育缺陷导致大脑皮层和海马中GABA能抑制过度。
  • USE OF ACTIVE PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS
    申请人:F. Hoffmann-La Roche AG
    公开号:EP2635277B1
    公开(公告)日:2018-12-19
  • USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS
    申请人:Gasser Rodolfo
    公开号:US20120115839A1
    公开(公告)日:2012-05-10
    The present invention relates to the pharmaceutical use of selective GABA A α5 negative allosteric modulators for the treatment, prevention and/or delay of progression of central nervous system (CNS) conditions related to excessive GABAergic inhibition in the brain.
查看更多